Adoptive transfer of T-cell immunity.

Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med (2005) 1.42

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med (2012) 1.07

CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity. Cell Mol Immunol (2011) 0.87

T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors. Am J Pathol (2003) 0.86

Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. Cancer Immunol Immunother (2011) 0.77

Adoptive transfer of T-cell immunity: gene transfer with MHC-restricted receptors. Trends Immunol (2002) 0.76

Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01

The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat Immunol (2006) 2.96

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92

Heterogeneous differentiation patterns of individual CD8+ T cells. Science (2013) 2.54

Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47

Antigen bias in T cell cross-priming. Science (2004) 1.82

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78

The cancer antigenome. EMBO J (2012) 1.78

Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77

Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science (2009) 1.70

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61

One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55

In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54

Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53

Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42

High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40

Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39

Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33

Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25

T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24

MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24

Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19

Generation of T cell help through a MHC class I-restricted TCR. J Immunol (2006) 1.15

Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 1.14

Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2011) 1.11

Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11

Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol (2007) 1.10

TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07

Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 1.06

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol (2011) 1.04

High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03

Requirements for effective antitumor responses of TCR transduced T cells. J Immunol (2008) 1.02

CD8+ T cell tolerance and cancer immunotherapy. J Immunother (2003) 1.01

Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol (2002) 1.01

Specificity and affinity motifs for Grb2 SH2-ligand interactions. Proc Natl Acad Sci U S A (2002) 1.01

The descent of memory T cells. Ann N Y Acad Sci (2011) 1.01

High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol (2009) 1.00

TCR repertoires of intratumoral T-cell subsets. Immunol Rev (2014) 1.00

Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium tuberculosis-specific CD4+ T cells. Hum Immunol (2005) 0.99

TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother (2009) 0.99

Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest (2013) 0.99

Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol (2004) 0.97

Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2005) 0.97

In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol (2007) 0.96

Class I major histocompatibility complexes loaded by a periodate trigger. J Am Chem Soc (2009) 0.95

An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol (2008) 0.94

Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine (2008) 0.94

Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr Protoc Immunol (2009) 0.92

T-cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol (2011) 0.90

Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology (2002) 0.90

Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol (2013) 0.89

The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1. Blood (2012) 0.89

The impact of self-tolerance on the polyclonal CD8+ T cell repertoire. J Immunol (2004) 0.88

UV-induced ligand exchange in MHC class I protein crystals. J Am Chem Soc (2009) 0.88

Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol (2002) 0.87

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res (2004) 0.87

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol (2002) 0.86

Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur J Immunol (2013) 0.84

Long-term functionality of TCR-transduced T cells in vivo. J Immunol (2008) 0.84

Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol Immunother (2007) 0.83

Optimizing the efficacy of epitope-directed DNA vaccination. J Immunol (2002) 0.82

IL-21-stimulated human plasmacytoid dendritic cells secrete granzyme B, which impairs their capacity to induce T-cell proliferation. Blood (2013) 0.82

NAB2 and EGR-1 exert opposite roles in regulating TRAIL expression in human Natural Killer cells. Immunol Lett (2013) 0.81

HLA micropolymorphisms strongly affect peptide-MHC multimer-based monitoring of antigen-specific CD8+ T cell responses. J Immunol (2013) 0.81

Technologies for MHC class I immunoproteomics. J Proteomics (2010) 0.81

The transcriptional regulator NAB2 reveals a two-step induction of TRAIL in activated plasmacytoid DCs. Eur J Immunol (2012) 0.79

Immunotherapeutic strategies: the melanoma example. Immunotherapy (2009) 0.79

Development of a hypersensitive periodate-cleavable amino acid that is methionine- and disulfide-compatible and its application in MHC exchange reagents for T cell characterisation. Chembiochem (2013) 0.78

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. Cancer Res (2008) 0.78

Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood (2007) 0.78

Intradermal vaccination by DNA tattooing. Methods Mol Biol (2014) 0.77

Vaccine leads to memory loss. Nat Med (2007) 0.77

Microbead-assisted retroviral transduction for clinical application. Hum Gene Ther (2010) 0.76

Better safe than sorry: TOB1 employs multiple parallel regulatory pathways to keep Th17 cells quiet. Eur J Immunol (2014) 0.75

Tumors hijack fetal enzyme, escape killer T cells. Nat Med (2003) 0.75

Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma. Nat Med (2016) 0.75

Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2017) 0.75

Gene transfer of MHC-restricted receptors. Methods Mol Med (2005) 0.75